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Edited by Michael R. BubbAbstract Neuroﬁlaments are synthesised in neuronal cell bodies
and then transported through axons. Damage to neuroﬁlament
transport is seen in amyotrophic lateral sclerosis (ALS). Here,
we show that PKN1, a neuroﬁlament head–rod domain kinase
is cleaved and activated in SOD1G93A transgenic mice that
are a model of ALS. Moreover, we demonstrate that glutamate,
a proposed toxic mechanism in ALS leads to caspase cleavage
and disruption of PKN1 in neurons. Finally, we demonstrate that
a cleaved form of PKN1 but not wild-type PKN1 disrupts neuro-
ﬁlament organisation and axonal transport. Thus, deregulation
of PKN1 may contribute to the pathogenic process in ALS.
 2008 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Protein kinase N (PKN) is a serine/threonine kinase that dis-
plays homology to PKC. PKN comprises three isoforms that
each harbour a C-terminal located catalytic domain and un-
ique N-terminal regulatory regions. PKN1 is the most abun-
dant isoform in neurons and is implicated in a variety of
functions including cytoskeletal organisation [1].
Neuroﬁlaments, the intermediate ﬁlaments of neurons are
one neuronal substrate for PKN1 [2]. Their major proteins
are neuroﬁlament light, middle and heavy chains (NFL,
NFM and NFH). Neuroﬁlaments are synthesised in neuronal
cell bodies and then transported through axons where they
control axonal calibre [3]. Dysfunction of neuroﬁlament
metabolism is strongly implicated in amyotrophic lateral scle-
rosis (ALS). Accumulations of neuroﬁlaments are a pathology
of ALS; mutations in NFL cause some forms of Charcot-Mar-Abbreviations: PKN, protein kinase N; NFL, NFM and NFH,
neuroﬁlament light middle and heavy chains; ALS, amyotrophic
lateral sclerosis
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doi:10.1016/j.febslet.2008.05.034ie-Tooth disease and modulating neuroﬁlament expression can
model ALS and alter disease progression in mice expressing
familial ALS-associated mutants of Cu/Zn superoxide dismu-
tase-1 (SOD1) [4]. The mechanisms by which neuroﬁlaments
accumulate in ALS involve damage to their axonal transport
and this is one of the earliest pathological changes seen in sev-
eral transgenic mouse models of ALS [5–7].
NFL, NFM and NFH each contain a central alpha-helical
rod domain that is ﬂanked by globular N-terminal head do-
mains and non-alpha-helical C-terminal domains. The head
domains are believed to regulate ﬁlament assembly and
PKN1 phosphorylates the head–rod domain of neuroﬁla-
ments; this phosphorylation disrupts neuroﬁlament assembly
in vitro [2]. However, the eﬀect of PKN1 on neuroﬁlament
organisation in vivo in neurons has not been reported and this
is an important omission since neuroﬁlaments display diﬀerent
assembly properties in vitro and in cells [8,9]. Moreover, how
any PKN1-induced changes in neuroﬁlament organisation
inﬂuence their axonal transport is likewise unknown. Finally,
any potential role of PKN1 in ALS has not yet been studied.
Here, we have investigated these topics.2. Materials and methods
All experiments were performed at least three times.
2.1. Reagents
Plasmids: rat GFP-NFM [10]; human FLAG-wild-type PKN1
(PKN1wt) and an N-terminal truncated constitutively-active form of
PKN1 (amino acids 561–942) (PKN1561–942) [11]; pCINeo-CAT
expressing the Escherichia coli chloramphenicol acetyl transferase gene
was used as a control to balance the numbers and amounts of plasmids
in experiments to investigate the eﬀects of PKN1 on neuroﬁlament
transport. Antibodies: PKNaC6 that detects a C-terminally located epi-
tope in PKN1 [11]; NA1216 antibody to NFM from Biomol, DM1a to
tubulin and FLAG antibody M2 from Sigma; SOD1 antibody from
Calbiochem. L-glutamate was obtained from Sigma and caspase inhib-
itors Z-VAD-FMK and Z-DEVD-FMK were obtained from Tocris.
Inhibitors were prepared according to manufacturers instructions.2.2. PKN1 kinase assays
PKN1 activity was determined using in vitro kinase assays with
myelin basic protein as substrate essentially as described [12]. PKN1
was isolated by immunoprecipitation using antibody PKNaC6 or anti-
body to the FLAG tag on transfected PKN1. Immunoblots conﬁrmed
equal amounts of immunoprecipitated PKN1. Reactions were stopped
after 20 min; pilot studies demonstrated that PKN1 activity was withinblished by Elsevier B.V. All rights reserved.
Fig. 1. Transfection of PKN1 elevates cellular PKN1 activity and
PKN1561–942 displays greater activity than PKN1wt. (A) shows in vitro
PKN1 assays of cells transfected with PKN1wt or CAT as a control.
The higher level of activity seen with the PKN1 compared to the
FLAG antibody may be because the PKN1 antibody pulls down
endogenous + transfected whereas the FLAG antibody pulls down
only transfected kinase. Also, the diﬀerent antibodies may diﬀerentially
immunoprecipitate active kinase. (B) shows assays from cells trans-
fected with PKN1wt or PKN1561–942; cells transfected with CAT are
again shown as a control. PKN1 was immunoprecipitated using either
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of primary antibody and demonstrated speciﬁcity of the assay. Sam-
ples were separated by SDS–PAGE and subjected to autoradiography.
Signals were quantiﬁed as described [12].
2.3. Neuronal culture, transfection and assays of neuroﬁlament axonal
transport and microscopy
Primary cortical neurons were prepared and transfected as described
[10,13]. Bulk axonal transport of neuroﬁlaments was analysed as de-
scribed [10,13,14]. Brieﬂy, neurons cultured for 7 days were co-trans-
fected with GFP-NFM and either PKN1wt, PKN1561–942 or
pCINeo-CAT as a control and the cells then ﬁxed at 180, 220, 240
and 260 min post-transfection. Images of GFP-NFM transfected cells
(approximately 50 per time point) were collected via a CCD camera
and the distances travelled by GFP-NFM through axons calculated
using Metamorph image analysis software. Data from these measure-
ments were then graphically plotted and statistically analysed as indi-
cated so as to determine the speed of overall bulk neuroﬁlament axonal
transport. Previous studies have shown that the average length of ax-
ons in these neurons is approximately 780 lm and that they are no
longer extending their primary axon; since measurements are made
up to only approximately 150 lm this assay thus measures the rate
of transport of neuroﬁlaments through axons and is not linked to ax-
onal growth [10]. Co-transfection of PKN1 was conﬁrmed by immuno-
staining for FLAG and selected samples were additionally stained for
tubulin to conﬁrm that GFP-NFM transport was not limited by axo-
nal length. Quantiﬁcation of ﬂuorescence signals from FLAG-tagged
PKN1 in neurons was as described [15].PKN antibody to isolate total (transfected plus endogenous PKN1) or
an antibody to the FLAG tag on transfected PKN1 as indicated; 
indicates omission of immunoprecipitating antibody as a control. Both
the Coomassie stained gels showing substrate and corresponding
autoradiographs are displayed.3. Results
3.1. Activation of PKN1 disrupts neuroﬁlament assembly and
axonal transport
To investigate the eﬀects of PKN1 on neuroﬁlament
organisation, we elevated PKN1 activity in neurons and
studied neuroﬁlament architecture by immunostaining. PKN1
activity was elevated by transfection of PKN1wt or a previ-
ously described constitutively-active isoform (PKN1561–942)
[11]. Transfection of PKN1wt led to an overall increase in
PKN1 activity that was demonstrated by in vitro kinase
assays using antibody PKNaC6 to immunoprecipitate total
(transfected plus endogenous) PKN1 and anti-FLAG to
speciﬁcally immunoprecipitate transfected PKN1wt (Fig. 1A).
However, transfected PKN1561–942 displayed higher levels of
activity than PKN1wt (Fig. 1B).
Despite the elevation of total PKN1 activity, transfection of
PKN1wt had no detectable eﬀect on neuroﬁlament organisa-
tion; ordered arrays of neuroﬁlaments were observed in both
perikaryal regions and throughout axons and these were not
noticeably diﬀerent to those seen in non-transfected cells (Fig.
2A and B). However, transfection of PKN1561–942 induced a
marked disruption to neuroﬁlament architecture within peri-
karyal regions. In these neurons, cell body accumulation of
neuroﬁlaments in focal aggregates was readily apparent (Fig.
2C and D). To eliminate the possibility that this disruption to
neuroﬁlaments was an eﬀect of diﬀerent levels of PKN1561–942
and PKN1wt in the neurons (despite them being in the same
vector) we quantiﬁed the levels of expression of transfected
PKN1 in individual neurons by capturing the ﬂuorescent signal
from the FLAG tags. This revealed that there were no diﬀer-
ences (one-way Anova, not shown). Thus, PKN1561–942 but
not PKN1wt disrupts neuroﬁlament architecture in neurons.
Neuroﬁlament organisation is linked to their axonal trans-
port; mutations that disrupt neuroﬁlament organisation also
disrupt their transport [13,16]. We therefore enquired whether
expression of PKN1wt or PKN1561–942 altered axonaltransport of neuroﬁlaments. To do so, we used a previously de-
scribed assay that involves monitoring movement of GFP-
NFM through axons of transfected rat cortical neurons
[10,13,14]. Whilst co-transfection of PKN1wt had no signiﬁ-
cant eﬀect on neuroﬁlament transport, co-transfection of
PKN1561–942 induced a marked inhibition in the movement
of neuroﬁlaments in this assay (Fig. 3).
3.2. Glutamate induces caspase-mediated cleavage and activation
of PKN1 in neurons
Glutamate excitotoxicity is strongly implicated in ALS [17].
We therefore monitored the eﬀect of glutamate exposure on
PKN1 in seven DIV cultured rat cortical neurons that are
known to express glutamate receptors and to respond to gluta-
mate treatment [10,18]. Short-term treatment with 100 lM glu-
tamate had little eﬀect on the electrophoretic mobility of
PKN1. However, extended treatments induced proteolysis of
PKN1 to generate an increasing number of N-terminally trun-
cated fragments whose appearance were maximal at 480 min
(Fig. 4A). LDH assays revealed no signiﬁcant loss of viability
of the neurons at his time point (data not shown) which is in
agreement with previous studies [10,19].
Caspase-3-induced cleavage of PKN1 to produce N-termi-
nally truncated, constitutively-active isoforms including
PKN1561–942 has been described in non-neuronal cells undergo-
ing apoptosis [11]. To determine whether glutamate-induced
cleavage in the cortical neurons also involved caspase-3, we
treated the neurons with the broad-spectrum caspase inhibitor
Z-VAD-FMK and the caspase-3 inhibitor Z-DEVD-FMK
prior to glutamate exposure. Both of these compounds inhib-
ited glutamate-induced cleavage of PKN1 in the neurons
(Fig. 4B). Moreover, PARP a known caspase substrate was
cleaved in the glutamate-treated neurons but NFL that is not
Fig. 2. Expression of PKN1561–942 but not PKN1wt disrupts neuroﬁlament organisation in rat cortical neurons. (A) shows normal distribution of
neuroﬁlaments in a non-transfected neuron. (B–D) show neuroﬁlaments in neurons co-transfected with PKN1wt (B) or with PKN1561–942 (C, D). In
(C) note the disruption to neuroﬁlaments in the PKN1561–942 transfected neuron (arrowhead) but not in its non-transfected near neighbour.
Neuroﬁlaments were detected using antibody NA1216 and PKN1wt/PKN1561–942 with FLAG antibody. Scale bars = 20 lm.
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eﬀect of glutamate on PKN1 activity. To do so, we performed
in vitro kinase assays on neurons following 480 min glutamate
treatment. Antibody PKNaC6 that detects a C-terminal epi-
tope was used to immunoprecipitate PKN1 so as to ensure that
both full-length and cleaved isoforms containing the kinase do-
main were isolated. These assays revealed that PKN1 activity
was elevated compared to untreated neurons (Fig. 4C).
3.3. PKN1 activity is elevated and PKN1 is proteolytically
cleaved in spinal cords of SOD1G93A transgenic mice
Mutations in SOD1 cause some familial forms of ALS.
Transgenic mice expressing mutant SOD1 are models ofALS with SOD1G93A mice being the best characterized [20].
We enquired whether proteolytic cleavage of PKN1 similar
to that observed in the glutamate-treated neurons occurs in
SOD1G93A mice. To do so, we performed immunoblots for
PKN1 in brain and spinal cords from SOD1G93A and control
littermate mice at 40, 80 and 120 days. On the inbred C57Bl/6
background used, these ages correspond to prior to any clini-
cal disease, early- and mid-stage disease.
We detected full-length PKN1 and also a further faster-
migrating species (approximately 65 kDa) in brains and spinal
cords of both SOD1G93A and control mice (Fig. 5A). We
were unable to eliminate the appearance of this faster-migrat-
ing PKN1 species using a range of diﬀerent methods to process
Fig. 3. PKN1561–942 but not PKN1wt disrupts axonal transport of neuroﬁlaments. (A) shows distances moved by GFP-NFM through axons of rat
cortical neurons co-transfected with CAT (control), PKN1wt or PKN1561–942 at diﬀerent time-points post-transfection as indicated. No signiﬁcant
diﬀerences were detected in GFP-NFM transport between CAT and PKN1wt co-transfected neurons at any time point. GFP-NFM in PKN1561–942
co-transfected neurons moved signiﬁcantly less than both CAT and PKN1wt co-transfected neurons (P 6 0.05 at 220 min; P 6 0.001 at 240 and
260 min; n = 35–60, Mann–Whitney). (B) shows representative images of GFP-NFM labelling in neurons co-transfected with PKN1 or PKN1561–942
at 260 min post-transfection; cells were stained with tubulin to show presence of axon. Scale bar = 50 lm.
Fig. 4. Glutamate induces caspase-mediated cleavage and activation of PKN1 in cultured cortical neurons. (A) shows immunoblot of PKN1 in
untreated neurons (Un) or neurons treated with 100 lM glutamate for 15–960 min as indicated. Also shown is cleavage of PARP, a known caspase
substrate, but not NFL, which is not a substrate, following glutamate treatment. (B) shows inhibition of glutamate-induced PKN1 cleavage (480 min
100 lM glutamate treatment) by pre-treatment with caspase inhibitors. Z-VAD-FMK and Z-DEVD-FMK were used at 100 lM and applied 2 h
prior to glutamate stimulation. (C) In vitro kinase assays for PKN1 activity in untreated neurons and neurons treated with 100 lM glutamate for
480 min. Both the Coomassie stained gel showing substrate and corresponding autoradiograph are shown along with reaction mix controls with no
substrate (RM). + and  refer to presence or absence of the PKN1 antibody in the immunoprecipitations to isolate PKN1. Glutamate induces a 2.07-
fold increase in activity (t-test; n = 7).
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tissues under normal circumstances.However, we observed the presence of an additional, 55 kDa
PKN1 species in the spinal cords but not brains of SOD1G93A
Fig. 5. PKN1 is cleaved and activated in SOD1G93A transgenic mice. (A) Immunoblots to show PKN1 in spinal cord (upper) and brain (lower)
from SOD1G93A and non-transgenic littermate (NT) mice at ages 40, 80 and 120 days. Full-length PKN1 (120 kDa) and an approx. 65 kDa species
are seen in all samples. An additional approx. 55 kDa migrating species (arrowhead) is seen in spinal cord but not brains of SOD1G93A mice at 80
and 120 days; this species is not detected in non-transgenic littermates. The samples were also probed with an antibody to SOD1 to conﬁrm the
genotype (bottom panel). Two mice at each age are shown but an additional two mice were analysed with highly similar results. (B) shows in vitro
kinase assays for PKN1 activity in spinal cords of SOD1G93A and non-transgenic littermate (NT) mice. Both the Coomassie stained gel showing
substrate and corresponding autoradiograph are shown along with reaction mix controls with no substrate (RM). + and  refer to presence or
absence of the PKN1 antibody in the immunoprecipitations to isolate PKN1. PKN1 activity is elevated approximately 2.25-fold in SOD1G93A mice
(n = 8, t-test).
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mice (Fig. 5A). Moreover, the 55 kDa PKN1 species was
clearly apparent in 80 and 120 day SOD1G93A mice but was
only weakly labelled or absent in 40 day mice indicating that
its appearance was linked to disease progression.
To enquire whether there were changes in PKN1 activity in
the spinal cords of SOD1G93A mice, we performed in vitro ki-
nase assays. These revealed that compared to non-transgenic
littermates, PKN1 activity was elevated in 120-day-old SOD1-
G93A mice (Fig. 5B). Whether this activation was directly
linked to PKN1 cleavage is not clear but is consistent with this
notion.4. Discussion
Here, we demonstrate that excitotoxic glutamate exposure
elevates PKN1 activity in neurons and also induces caspase-
mediated cleavage of PKN1 to produce N-terminally truncated
species. Such truncated PKN1 species behave as constitutively-
active isoforms [11]. We also demonstrate that PKN1 activity is
elevated in spinal cords of SOD1G93A transgenic mice and
that PKN undergoes processing to produce additional N-termi-
nally truncated PKN1 species in the spinal cords but not brains
of these animals. Thus, both glutamate and ALS mutant SOD1
induce activation and cleavage of PKN1.
In cultured neurons, glutamate-induced cleavage of PKN1
involved caspase-3 type proteases. This is in agreement with
earlier studies in non-neuronal cells [11]. Although the mecha-
nisms by which mutant SOD1 causes ALS are not fully under-
stood, there is strong evidence that disruption to glutamate
handling contributes to the pathogenic process [17]. Moreover,caspase-3 is activated in SOD1G93A mice when animals ﬁrst
become symptomatic [21] and this is where we observe addi-
tional cleaved PKN1 species in the spinal cords of these ani-
mals. Thus, it seems likely that processing of PKN1 in the
SOD1G93A mice also involves caspase-3. Interestingly, cleav-
age of PKN1 has also been observed in models of stroke [22].
Damage to axonal transport is one of the earliest patholog-
ical features in ALS and this includes disruption to transport
of neuroﬁlaments [5–7,15]. Increased phosphorylation of
NFM/NFH side-arms is seen in cell bodies in ALS and phos-
phorylation of these domains slows neuroﬁlament transport
[10,14,23]. However, mutation of NFL head and rod domains
(that does not involve changes to NFM/NFH side-arm phos-
phorylation) also perturbs neuroﬁlament transport [13,16]
and the proper assembly of neuroﬁlaments is now known to
be an essential requirement for their transport [24]. PKN1
phosphorylates the head–rod domains of neuroﬁlaments in vi-
tro [2] and phosphorylation of this region (in particular the
head domain of NFL) regulates neuroﬁlament assembly [3].
Our ﬁndings that PKN1561–942 markedly disrupts both neuro-
ﬁlament organisation and transport therefore suggest that at
least part of these disruptions are via changes to neuroﬁlament
head–rod phosphorylation. It is also possible that PKN1561–942
targets other components of axonal transport, e.g. molecular
motors. Future studies to identify the residues phosphorylated
by PKN1 in neuroﬁlaments will help clarify this issue.
It is noteworthy that whilst transfection of PKN1wt or
PKN1561–942 both elevated cellular PKN1 activity, only
PKN1561–942 induced damage to neuroﬁlament organisation
and transport. The N-terminal regions deleted in PKN1561–942
(andwhich are likewise deleted in the glutamate-treated neurons
and SOD1G93A transgenic mice) are inhibitory to PKN1
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involved in targeting PKN1 to particular subcellular sites [25].
Thus, N-terminally deleted PKN1 isoformsmay be targeted dif-
ferently to neuroﬁlaments and/or other substrates to induce
damage to axonal transport. Interestingly, the cdk5 activator
p35 (another neuroﬁlament kinase) is also processed in mutant
SOD1 transgenic mice and this processing removes an N-termi-
nal myristylation signal that alters kinase distribution [26].
Clearly, the cellular transfection studies that demonstrate
perturbation of neuroﬁlament organisation and transport with
PKN1561–942 but not PKN1wt involve overexpression and this
is not the case in SOD1G93A transgenic mice where cleavage
of endogenous levels of PKN1 occurs. Whether such endoge-
nous levels of cleaved PKN1 are suﬃcient to generate disrup-
tion of neuroﬁlaments is not clear. One possibility is that at
least part of the disease process reﬂects a cumulative eﬀect of
low levels of cleaved PKN1 and this may account for the acute
eﬀects seen to neuroﬁlaments in the transfected neurons
whereas neuroﬁlament disruption takes several months in
SOD1G93A transgenic mice. Future studies to monitor the ef-
fects of PKN1 inhibitors (once speciﬁc ones are developed) on
neuroﬁlament organisation and transport, and disease progres-
sion in SOD1G93A transgenic might resolve this issue.
Despite the activation of caspase 3 in SOD1G93A transgenic
mice, there is dispute over whether motor neurons die by apop-
tosis [27]. Indeed, damage to axons is now known to be a prin-
cipal early feature of disease in these animals [28]. Our
demonstration that deregulation of PKN1 can damage axonal
transport therefore suggests a novel mechanism to link caspase
3 to ALS. Thus caspase-mediated processing of PKN1 induced
by glutamate or other disease-associated insults may alter neu-
roﬁlament head domain phosphorylation, organisation and
transport. As such, abnormal PKN1 signalling may contribute
to ALS.
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